Table 3.
Shows the numbers in each study group analyzed at 12 months postoperatively
| Outcome 12 m | Group | Total | X2 | P | ||
|---|---|---|---|---|---|---|
|
|
||||||
| Group A (with BCECF-AM) | Group B (with MMC) | Group C (control group) | ||||
| Complete success | ||||||
| Count | 14 | 18 | 11 | 43 | 3.4 | 0.49 |
| % within group | 56.0% | 75.0% | 50.0% | 60.6% | ||
| Qualified success | ||||||
| Count | 8 | 4 | 8 | 20 | ||
| % within group | 32.0% | 16.7% | 36.4% | 28.2% | ||
| Failure | ||||||
| Count | 3 | 2 | 3 | 8 | ||
| % within group | 12.0% | 8.3% | 13.6% | 11.3% | ||
| Total | ||||||
| Count | 25 | 24 | 22 | 71 | ||
| % within group | 100.0% | 100.0% | 100.0% | 100.0% | ||
Abbreviations: BCECF-AM, 2′,7′-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester; MMC, mitomycin C.